Document is current
Any future updates will be listed below
-
Authors
Sinigiani, Giulio
Milani, Paolo
De Michieli, Laura
Sanna, Giuseppe Damiano
Perlini, Stefano
Cipriani, Alberto
Palladini, Giovanni
-
Funding
Funding for this research was provided by:
Università degli Studi di Padova
- License Information
-
More Information
Article History
Received: 15 October 2025
Revised: 3 December 2025
Accepted: 4 December 2025
First Online: 22 December 2025
Declarations
:
: The authors declare no competing interests.
: Dr Sinigiani has received travel support from Alnylam and Pfizer. Prof Cipriani has received consulting income from AstraZeneca, and has advisory role for Pfizer, AstraZeneca, Alnylam and Bayer. Prof Palladini has advisory role for Alexion, Abbvie, Bayer, GSK, Life Molecular Science, Neuroimmune, Protego, Pfizer, Prothena, Regeneron, and has received honoraria from Janssen. Prof Milani has received honoraria from Jansen, Prothena, Pfizer, Bayer, Sebia and has advisory role for Siemens. Dr Sanna has received Cardiac ATTR Amyloidosis Fellowship grant funded by International Society of Amyloidosis (2023–2024); honoraria for lectures/teaching courses and travel support to attend scientific meetings: (Alnylam 2023–2024), AstraZeneca (2024), Pfizer (2024). L. De Michieli has received honoraria or travel grants from Pfizer Inc, Alnylam Pharmaceuticals, AstraZeneca Spa, Takeda Pharmaceutical, Chiesi, Sanofi and Euro Medica. Prof. Stefano Perlini has advisory role for Pfizer, AstraZeneca, Alnylam, Bayer and Prothena, and has received honoraria from Prothena, Pfizer, and AstraZeneca. The remaining authors have nothing to disclose.
